Bicara Therapeutics announces the first patients enrolled in Fortifi-Hn01, the main phase 2/3 of the clinical test of ficerafusp alpha in 1l repetitive/metastatic carcinoma of the squamous cell and neck cells

admin4 hours ago

0 0 Less than a minute